

SPHHP Research Activities Newsletter

University at Buffalo

August 2019

IN THE NEWS


Congratulations to the Following Awardees!



Amanda Crandall, PhD student in Community Health and Health Behavior received a continuation fellowship award from the National Institute of Diabetes and Digestive and Kidney Diseases/NIH for the project entitled, *An Investigation of the Effects of Food Scarcity on Reinforcement Policy among Parents and Offspring*. The study will continue to examine the effects of financial food scarcity on food reinforcement and delay discounting among children and adolescents to improve our understanding of the risk factors for obesity. **Jennifer Temple**, Associate Professor of Exercise and Nutrition Sciences, serves as Ms. Crandall's mentor.



Gregory Homish, Professor and Interim Chair of Community Health and Health Behavior, is PI on a continuation award from National Institute on Drug Abuse/NIH, for the project entitled, *Substance Use in Reservists: Social and Environmental Influences*. The longitudinal study is in its 7th year and continues to examine the impact of two military experiences - never being deployed and separation from military – on substance use outcomes for both soldiers and their spouses.



Blair Johnson, Assistant Professor of Exercise and Nutrition Sciences, received the Presidential Early Career Award for Scientists and Engineers (PECASE). This award is the highest honor bestowed by the U.S. Government to outstanding scientists and engineers who are in the early stages of their independent research careers. Recipients, who are nominated by participating federal agencies, are selected for their pursuit of innovative research at the frontiers of science and technology and for their commitment to community service as demonstrated through scientific leadership, public education, or community outreach.



Lucia Leone, Assistant Professor of Community Health and Health Behavior, is PI on a new award from the Food Lion FEEDS Charitable Foundation for the project entitled, *Veggie Van in North Carolina*. The funding will allow an additional two North Carolina based organizations to participate in the Veggie Van Study, which focuses on the development and evaluation of a mobile produce market to bring fresh, local, affordable food to lower income and under-served communities.



Lina Mu, Associate Professor of Epidemiology and Environmental Health, is PI on a continuation award from the National Institute of Environment Health Sciences/NIH for the project entitled, *Metabolomics Profiling of Biological Responses to Changes in Air Pollution Levels*. The research will continue to evaluate metabolic changes in response to air pollution exposure and provide insight on potential mechanisms through which air pollution may increase the risk of various diseases.

Matthew Bonner, Associate Professor of Epidemiology and Environmental Health and **Rachel Hageman Blair**, Associate Professor of Biostatistics, are Co-Is.

Inside this issue:

In the News	1-2
Grant Clinic	3-5
NIH Funding	
Limited Submissions	5
RFA	6-9
PAS	9
PAR	9-10
NIH Fellowships	10
Robert Wood Johnson	10
Words to Live By	10



Vijaya Prakash Krishnan Muthaiah, Assistant Professor of Rehabilitation Science, is PI on a new award from the Hearing Health Foundation for the research project entitled, *Potential of Inhibition of Poly ADP Ribose Polymerase as a Therapeutic Approach in Blast Induced Cochlear and Brain Injury*. The study will explore the potential of PARP inhibition as a potential therapeutic approach for blast-induced auditory neurodegeneration in both the peripheral and central auditory system.



Ekaterina Noyes, Professor of Epidemiology and Environmental Health, is Curriculum Director on a continuation award from the National Heart, Lung, and Blood Institute/NIH (PIs: Ranjit Singh and John Canty, Medicine) for the project entitled, *UB Clinical Scholar Program in Implementation Science to Achieve Triple Aims*. The program trains and prepares clinician scientists for academic leadership and independent research careers in dissemination and implementation science related to heart, lung, blood, and sleep disorders with associated risk factors and complexities.



Sharon Ray, Clinical Associate Professor of Rehabilitation Science, is PI on a new award from the J. Warren Perry and Charles Donald Perry Memorial Fund/ Community Foundation for Greater Buffalo for the project entitled, *Empowering Teachers to Sustain Assistive Technology Use in Underserved Schools*. The project will develop a sustainable system of training and resources that will enable teachers in an underserved school district to implement assistive technology into their classrooms to benefit students (with or without disabilities); and help bridge the divide of academic achievement. **Joe Lane**, Director of Center for Assistive Technology, is Co-I.



Jennifer Temple, Associate Professor of Exercise and Nutrition Sciences, and **Lucia Leone**, Assistant Professor Community Health and Health Behavior, are Co-Is (PI: Leonard Epstein, Pediatrics) on a continuation award from Eunice Kennedy Shriver National Institute of Child Health & Human Development/NIH for the project entitled, *Can Reinforcing Alternatives to Food Prevent Weight Gain in Children?* The study will continue to study individual differences in reinforcing value of food and alternatives to food in the home environment, providing the first test of the potential protective effect of strong alternative reinforcers to food for risk of weight gain in children.



Gregory Wilding, Professor and Chair of Biostatistics, is Co-I on two continuation awards. The first, from the National Institute of Nursing Research/NIH (PI: Grace Dean, Nursing), is entitled, *Efficacy of Nurse-Delivered Brief Behavioral Treatment to Self-Manage Insomnia in Cancer Survivors*. The study will continue to test a self-management behavioral intervention for cancer survivors with insomnia in order to reduce disease burden, improve well-being, strengthen self-determination and participation in health care, and prevent illness and complications.

The second, from the National Institute of Dental & Craniofacial Research/NIH (PI: Michelle Visser, Oral Biology), is entitled *The Role of Oral Spirochete Virulence Factors in the Impairment of Neutrophil Response*. The study seeks to understand how oral treponemese modulate neutrophil response leads to periodontal disease and the development of potentially active therapeutic molecules will lead to the improvement of oral and systemic health.



Guan Yu, Assistant Professor of Biostatistics, is Co-I on a continuation award (PI: Jill Kramer, Oral Biology) from the National Institute of Dental & Craniofacial Research/NIH for the project entitled, *Analysis of B Cell Activation by Endogenous Mediators of Inflammation in Sjogrens Syndrome*. The study will continue to examine the role of damage-associated molecular patterns (DAMPs) in primary Sjögren's Syndrome and other autoimmune diseases that are characterized by DAMP-mediated inflammation, such as systemic lupus and rheumatoid arthritis.



Jiwei Zhao, Assistant Professor of Biostatistics, is Co-I on a new award (PI: David Jacobs, Pharmacy) from the ASHP Research and Education Foundation for the project entitled *Impact of an Integrated Pharmacist and Primary Care Collaborative Transitions of Care Program on Clinical and Economic Outcomes among High Risk Patients*. The study's objective is to demonstrate that a multifaceted pharmacist intervention within a multidisciplinary patient-centered medical home transitional care program can reduce healthcare utilization and ultimately translate healthcare savings into a sustainable reimbursement model for pharmacists.

GRANT CLINIC

NIH Extramural Repayment Loan Programs (LRPs) Application Period will be Open **09/01/19 – 11/15/19**

The LRPs are a set of programs established by Congress and designed to recruit and retain highly qualified health professionals into biomedical or biobehavioral research careers. The NIH invites qualified health professionals who contractually agree to engage in NIH mission-relevant research for an average of at least 20 hours each week for at least two years, initially, to apply for an award in the Extramural LRP. The award will repay up to \$50,000 annually of a researcher's qualified educational debt. Research funding from NIH is not required to participate in the Extramural LRPs. Additional information about each LRP is provided [here](#).

New NIH Requirement for Fellowships and Career Development Grants ([NOT-OD-19-909](#))

Pre-Award

Beginning with receipt dates on or after **January 25, 2020**, NIH will require PIs for individual fellowships (fellows) and career development awards (faculty) to create an **ORCID** account and to link it to their NIH eRA Commons account. This will apply to F and K proposals. The December 8, 2019 Fellowship round will not have this requirement, but will be required for the April 8, 2020 deadline. eRA system validations will check whether applicants have ORCID IDs and **applications will not be accepted** unless an ORCID ID is linked to the PD/PI's eRA Commons Personal Profile.

Post-Award

Starting **October 1, 2019**, NIH will require trainees, scholars, and participants supported by institutional research training, career development, and research education awards (T03, T15, T32, T35, K12, KL2, R25, etc) that require appointments through the xTrain system to have an ORCID ID and to have it linked to their NIH eRA account. Note that xTrain appointments will not be accepted if potential appointees do not have an ORCID ID linked to their eRA personal profile starting October 1, 2019.

NIH NOTICES

[NOT-OD-19-114](#)

Reminders of NIH Policies on Other Support and on Policies Related to Financial Conflicts of Interest and Foreign Components

OTHER SUPPORT

Other Support includes **all** resources made available to a researcher in support of and/or related to **all** of their research endeavors, regardless of whether or not they have monetary value and regardless of whether they are based at the institution the researcher identifies for the current grant. This includes resource and/or financial support from all foreign and domestic entities, including but not limited to, financial support for laboratory personnel, and provision of high-value materials that are not freely available (e.g., biologics, chemical, model systems, technology, etc.).

FOREIGN COMPONENTS

NIH requires recipients to determine whether activities it supports include a foreign component, defined as *the existence of any "significant scientific element or segment of a project" outside of the United States*, in other words;

1. performance of work by a researcher or recipient in a foreign location, whether or not NIH grant funds are expended and/or 2. performance of work by a researcher in a foreign location employed or paid for by a foreign organization, whether or not NIH grant funds are expended.

FINANCIAL CONFLICT OF INTEREST

The FCOI regulation specifies the minimum requirements for investigators to disclose to their institution their significant financial interests. As outlined previously in [NOT-OD-18-160](#), the requirement to disclose includes financial interests received from a foreign entity. This requirement is distinct and in addition to the reporting of other support and foreign components to the NIH.

For additional information and requirements, please refer to the NIH notice.

[NOT-OD-19-125](#)

System Change and Procedure for Requesting an Extension to Early State Investigator (ESI) Status

Beginning on **August 22, 2019**, investigators will be able to request an extension to their ESI eligibility period through eRA Commons via an ESI Extension request button in the Education section of their Personal Profile. The system will provide text fields for individuals to provide a justification for the proposed extension, and the ability to upload PDFs of supporting documentation. Once completed and submitted, the request will be reviewed by the ESI Extension Committee. If approved by the Committee, the new ESI end date will appear in the Education section of their Personal Profile.

[NOT-OD-19-126](#)

Extension of Certain Flexibilities for Prospective Basic Experimental Studies with Human Participants

Policies regarding registration and results reporting for a subset of NIH-funded research whose primary purpose is basic experimental studies with humans (BESH) have been extended until September 24, 2021. While extending the period of delayed reinforcement, NIH continues to expect registration and results reporting, but with the additional flexibility to register and report results on alternative publicly available platforms. Plans for meeting the NIH reporting expectations using an alternative platform should be described at the time of application in the Dissemination Plan attachment. Please see the NIH notice for additional information.

[NOT-MH-19-031](#)

Consolidated Notice on NIMH Clinical Trials Practice

NIMH supports clinical trials in the following manner:

Studies primarily focused on testing or confirming Efficacy/Effectiveness/Safety of an intervention may be submitted to:

- [NIMH-specific Clinical Trials RFAs](#)
- Selected Funding Opportunity Announcements (FOAs) that allow clinical trials applications (i.e., designated as either “Clinical Trials Optional” or “Clinical Trials Required”), such as:
 - ✦ NIMH initiated FOAs;
 - ✦ FOAs from other Institutes/Centers on which NIMH participates;
 - ✦ Parent Announcements for Career Development Awards (K), Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR).

NIMH **does not** accept clinical trial applications that propose to test the safety or demonstrate efficacy or effectiveness of an intervention under the following parent FOAs and their re-issuances: [PA-19-055](#) (R01), [PA-19-091](#) (R01 BESH), [PA-19-054](#) (R21), and [PA-19-092](#) (R21 BESH). Additionally, NIMH **does not** accept any type of clinical trial application submitted under FOAs that are “Clinical Trials Not Allowed.”

[NOT-GM-19-049](#)

Notice of Change To Award Project Period in PAR-19-253, “Focused Technology Research and Development (R01) – clinical trial not allowed”

The FOA is modified accordingly:

Current language: The scope of the proposed project should determine the project period. The maximum project period is 4 years, 5 for early stage investigators. The grant may be renewed only one time.

Revised language: The scope of the proposed project should determine the project period. The maximum project period is 5 years. The grant may be renewed only one time.

NIH Notices of Special Interest

If you will be applying under any of the special interest topics listed below, please indicate so, including the NIH Notice number in the Comments box of the RAS Questionnaire. The RAS staff will ensure that this information is included with the application to NIH.

[NOT-DA-19-037](#)

Health Services and Economic Research on the Treatment of Drug, Alcohol, and Tobacco Use Disorders

The National Institute on Drug Abuse ([NIDA](#)) seeks research on rigorous hypothesis-driven and theory-based study designs and data analytic methods that will support a new generation of addiction health services research. Examples of such research include: (1) clinical quality improvement; (2) quality improvement in services organization and management; (3) implementation science; (4) availability, demand, access, and financing; (5) effectiveness; and (6) development or improvement of research methodology, analytic approaches, and measurement instrumentation.

[NOT-OD-19-041](#)

The Application of Big Analytics to Drug Abuse Research

NIDA is interested in harnessing big data analytics to gain new knowledge related to the neurobiological and behavioral changes that are consequences of, or that underlie, drug use and addiction. Analyses may involve one or more data sets or knowledge sources but should address fundamental research questions associated with substance abuse research and also develop computational tools (e.g., aggregated datasets, standards, analytic software) facilitating future analysis of substance abuse research data

[NOT-OD-19-048](#)

Research to Prevent Drug Use, Misuse and Addiction

NIDA is interested in prevention science research that spans efficacy, effectiveness and services research. Primary outcomes of interest include preventing initiation of substance use, misuse and progression to disorder, as well as prevention of drug related HIV infection. NIDA encourages intervention development work that articulates theoretical and conceptual models identifying and justifying the selection of intervention targets.

Please refer to the NIH notices for additional information, including appropriate FOAs.

Notices of Intent to Publish a Funding Opportunity Announcement

[NOT-CA-19-063](#)

Improving the Reach and Quality of Cancer Care in Rural Populations (R01) – clinical trial required; reissuance of RFA-CA-18-026; expected release: Fall 2019; anticipated due date early Winter 2020.

[NOT-DA-19-035](#)

Accelerating the Pace of Drug Abuse Research Using Existing Data (R01) – clinical trial optional; expected release: September 2019; anticipated first due date: February 2020

[NOT-DA-19-059](#)

NIDA Program Project Grant Applications (P01) – clinical trial optional; reissuance expected September 8, 2020; anticipated first due date: January 2020

NIH FUNDING OPPORTUNITIES

LIMITED SUBMISSIONS

Prior approval from UB is required for the following funding opportunities. If you are interested in applying to any of the **limited submissions** listed below, please provide the OVPRED with notification through the [Limited Submissions Mailbox](#) at least 60 days prior to the sponsor's submission deadline before proceeding with an application. As of August 8, 2019, the Limited Submission Program is being managed by Dr. Joseph Balthasar on behalf of the OVPRED. Within the OVPRED, Dr. Balthasar has been appointed Executive Director of Research Initiatives. He may be contacted at jb@buffalo.edu or by phone at 645-3321 for any questions or advice about the limited submission process.

[RFA-DK-19-002 \(P30\)](#) – clinical trial optional

Nutrition Obesity Research Centers (NORCs)

The mission of the NORC program is to serve as a key component of the NIDDK-supported research effort to advance nutrition and obesity research. The NORCs promote new discoveries and enhance scientific progress through support of cutting-edge basic, clinical, and translational research in nutrition science and obesity with the ultimate goal of improving public health. *Only one application per institute is allowed.* **Application Due Date:** October 23, 2019

[RFA-CA-19-057 \(F99/K00\)](#)

The NCI Predoctoral to Postdoctoral Fellow Transition Award

The objective of this award is to identify and encourage outstanding graduate students who are recognized by their institutions as having high potential and strong interest in pursuing careers as independent cancer researchers, and then to facilitate their successful transition to postdoctoral positions. The F99/K00 award is intended for individuals who require 1-2 years to complete their Ph.D. dissertation research training (F99 phase) before transitioning to mentored postdoctoral research training (K00 phase). Consequently, applicants are expected to propose an individualized research training plan for the next 1-2 years of dissertation research training and a plan for 3-4 years of mentored postdoctoral research and career development activities that will prepare them for independent cancer-focused research careers. *Only one application per institute is allowed.* **Application Due Date:** December 4, 2019

REQUESTS FOR APPLICATIONS (RFA)

October Due Dates

[RFA-HL-20-003 \(UG3/UH3\)](#) – clinical trial optional

[RFA-HL-20-004 \(U24\)](#) – clinical trial not allowed

Disparities Elimination through Coordinated Interventions to Prevent and Control Heart and Lung Disease Risk (DECIPHeR)

The UG3/UH3 invites applications for projects that propose to test late-stage (T4) implementation research strategies for optimally and sustainably delivering proven-effective, evidence-based multi-level interventions to reduce or eliminate cardiovascular and/or pulmonary health disparities, and that promote and improve population health in high-burden communities. The U24 invites applications for a Research Coordinating Center (RCC) to support projects from the UG3/UH3. The RCC will coordinate activities across all of the DECIPHeR projects.

Application Due Date: October 1, 2019

[RFA-HL-17-022 \(R21\)](#)

Maximizing the Scientific Value of the NHLBI Biorepository: Scientific Opportunities for Exploratory Research

This FOA will support meritorious exploratory research relevant to the [NHLBI mission](#) using the existing biospecimen collections that are stored in the NHLBI Biologic Specimen Repository, thereby maximizing the scientific value of the stored collections and providing researchers with an opportunity to generate preliminary data for subsequent research proposals. **Application Due Date:** October 17, 2019

[RFA-AG-20-022 \(R01\)](#) – clinical trial optional

Aging, Driving and Early Detection of Dementia

This FOA invites applications to conduct new research on automobile technology for signaling early signs of cognitive impairment in older drivers. Two general kinds of research are envisioned: 1. Basic – intended to identify unobtrusive technology for monitoring driving performance and integrating it with other data to detect cognitive impairment, and 2. Methodological - intended to integrate driving-related data (and databases) with data on an individual's health and functional status to detect cognitive impairment. **Application Due Date:** October 22, 2019

[RFA-AG-20-010 \(K76\)](#) – clinical trial not allowed; [RFA-AG-20-011 \(K76\)](#) – clinical trial required

Paul B. Beeson Emerging Leaders Career Development Award in Aging

These FOAs invited early-stage investigators who have begun to establish research programs and who, through this award, will be ready to assume leadership roles in their field of expertise and be poised to change theory, practice, and health outcomes related to the health of older individuals. Unlike other mentored K awards, candidates for this award must have received competitively awarded research support as a Program Director/Primary Investigator (PD/PI) at the faculty level or have otherwise leveraged faculty-level research support to develop an independent line of research.

Application Due Date: October 22, 2019

[RFA-AG-20-006 \(R01\)](#) – clinical trial optional

Interpersonal Processes in Alzheimer's Disease and Related Dementias: Clinical Interactions and Care Partnerships

The goal of this initiative is to support research that can lead to the development of interventions for optimizing communication among patients, caregivers, and healthcare practitioners and for preserving strong and supportive caregiving relationships throughout disease progression along the continuum of care for people with AD/ADRD.

Application Due Date: October 23, 2019

[RFA-AG-20-030 \(R01\)](#) – clinical trial not allowed

Microbiome and Aging: Impact on Health and Disease

This FOA invites projects focused on defining the factors that influence microbiome composition and functional characteristics during aging, understanding how the aging microbiome relates to the causes and pathophysiology of age-related chronic diseases, and development and testing of targeted interventions through diet, drugs, or live organisms. This FOA will accept basic mechanistic, preclinical studies in animal models and human studies leveraging existing human longitudinal cohorts. **Application Due Date:** October 30, 2019

[RFA-NS-19-031 \(P50\)](#) – clinical trial optional

Senator Paul D. Wellstone Muscular Dystrophy Specialized Research Centers (MDSRC)

These Centers promote collaborative basic, translational and clinical research and provide important resources that can be used by the national muscular dystrophy research communities. The Centers also provide outstanding environments for the training of new researchers capable of addressing high priority research objectives in the muscular dystrophies.

Application Due Date: October 31, 2019

November Due Dates

[RFA-AT-20-001 \(R21\)](#) – clinical trial not allowed

Preclinical Screening for Natural Product Drug Interactions

This FOA solicits applications that seek to identify natural products with the potential to inhibit or induce Phase I and Phase II drug metabolizing enzymes and drug transporters, thereby possibly contributing to pharmacokinetic interactions with other medications. **Application Due Date:** November 1, 2019

[RFA-DA-20-013 \(R01\)](#) – clinical trial optional

PrEP for HIV Prevention among Substance Using Populations

NIDA is interested in research that addresses research gaps related to PrEP and its use among substance users, with the goals of improving PrEP management and implementation. Only one clinical trial has evaluated PrEP among people who inject drugs and systematic data regarding the broader use of PrEP among substance users are limited. There is a need to better understand the effects of substance use on PrEP effectiveness and better inform PrEP implementation among substance users. **Application Due Date:** November 8, 2019

[RFA-OD-18-005 \(K01\)](#) – clinical trial not allowed; [RFA-OD-18-006 \(K01\)](#) – clinical trial required

Mentored Research Scientist Career Development Award in Tobacco Regulatory Research

These FOAs provide support and protected time (three, four, or five years) for an intensive, supervised career development experience in biomedical, behavioral, and social science research that will inform the development and evaluation of regulations on tobacco product manufacturing, distribution, and marketing and that will lead to research independence. **Application Due Dates:** November 8, 2019

[RFA-NS-18-043 \(R01\)](#); [RFA-NS-18-042 \(R21\)](#) – clinical trial not allowed

Discovery and Validation of Novel Targets for Safe and Effective Pain Treatment

These FOAs promote the discovery and validation of novel therapeutic targets to facilitate the development of pain therapeutics. Specifically, the focus is on the basic science discovery of targets in the peripheral nervous system, central nervous system, immune system or other tissues in the body that can be used to develop treatments that have minimal side effects and little to no abuse/addiction liability. **Application Due Dates:** November 12, 2019

[RFA-DA-20-008 \(R01\)](#); [RFA-DA-20-009 \(R21\)](#) – clinical trial not allowed

Leveraging Big Data Science to Elucidate the Mechanisms of HIV Activity and Interaction with Substance Use Disorder

The purpose of these FOAs is to attract data and computational scientists to propose novel ways to integrate data of different types and scales to allow new types of analysis through big data science approaches. It is expected that the development and application of novel computational, bioinformatics, statistical, and analytical approaches can be leveraged to reveal the effects of the interaction of the HIV virus and drugs of abuse on viral activity, latency, and disease progression, as well as new aspects of addiction biology. **Application Due Date:** November 14, 2019

[RFA-AA-20-001 \(P50\)](#) – clinical trial optional

Specialized Alcohol Research Centers

The Specialized Alcohol Research Center provides a mechanism for fostering interdisciplinary cooperation within a group of established investigators conducting exceptional alcohol research. Therefore, existence of a strong research capability is fundamental to the establishment of a new Center or the continuation of an existing Center. A Center should be an identifiable organizational unit within an institutional or organizational structure such as a university, medical center, or a consortium of affiliated cooperating institutions. **Application Due Date:** November 14, 2019

[RFA-AA-20-002 \(P60\)](#) – clinical trial optional

Comprehensive Alcohol Research Centers

This mechanism supports an integrated, broad-based multidisciplinary, multi-investigator, long-term program of research and research support activities planned around a specific major research theme. In addition, a Comprehensive Alcohol Research Center is required to develop an effective information dissemination component to help accelerate the use of research findings for the benefit of public health (Dissemination Core). **Application Due Date:** November 14, 2019

[RFA-AI-19-045 \(UM1\)](#) – clinical trial required

HIV/AIDS Clinical Trials Units

Applications are solicited for Clinical Trials Units to provide scientific and administrative expertise as well as the infrastructure to conduct clinical studies developed by NIH HIV/AIDS Clinical Trials Networks. Clinical Trials Units will participate in the development of trials and provide clinical sites, local laboratory capacity, and pharmacy support for two or more HIV/AIDS Clinical Trials Networks. **Application Due Date:** November 18, 2019

[RFA-CA-19-039 \(U01\)](#) – clinical trial optional

Early-Stage Development of Informatics Technologies for Cancer Research and Management

This FOA invites applications for the development of enabling informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum and focuses on early-stage development from prototyping to hardening and adaptation. **Application Due Date:** November 20, 2019

[RFA-CA-19-040 \(U24\)](#) – clinical trial optional

Advanced Development of Informatics Technologies for Cancer Research and Management

This FOA focuses on emerging informatics technology, defined as one that has passed the initial prototyping and pilot development stage, has demonstrated potential to have a significant and broader impact, has compelling reasons for further improvement and enhancement, and has not been widely adopted in the cancer research field.

Application Due Dates: November 20, 2019

[RFA-CA-19-041 \(U24\)](#) – clinical trial optional

Sustained Support for Informatics Technologies for Cancer Research and Management

The focus of this FOA is on sustaining operations and improving the user experience and availability of existing, widely-adopted informatics tools and resources. This is in contrast to early-stage and advanced development efforts to generate these tools and resources that are supported by the companion FOAs.

Application Due Dates: November 20, 2019

[RFA-AT-20-002 \(U54\)](#) – clinical trial required

Center of Excellence for Natural Product Drug Interaction Research

This FOA solicits applications for a Center of Excellence for Natural Product Drug Interaction Research to provide leadership in the study of natural product drug interactions. The ultimate goals of this program are to 1) clearly establish the clinical relevance of pharmacokinetic interactions from a select number of natural products, and 2) provide guidance and leadership to the broader research community on how best to research metabolism mediated drug interactions involving complex natural products. **Application Due Date:** November 22, 2019

Multiple Due Dates

[RFA-OD-19-021 \(R21\)](#) – clinical trial not allowed

Maximizing the Scientific Value of Existing Biospecimen Collections: Scientific Opportunities for Exploratory Research

This FOA invites applications to stimulate exploratory research relevant to the mission of the Food and Drug Administration (FDA) - Center for Tobacco Products (CTP) using existing (publicly available) biospecimens currently stored in repositories in the United States. Research results from this FOA are expected to generate findings and data that are directly relevant in informing the FDA's regulation of the manufacture, distribution, and marketing of tobacco products to protect public health. **Application Due Dates:** October 8, 2019, August 7, 2020, March 8, 2021

[RFA-OD-19-022 \(R21\)](#) – clinical trial not allowed

Secondary Analyses of Existing Datasets of Tobacco Use and Health

This FOA supports research proposing the innovative analysis of existing (publicly available) nationally representative U.S. cross-sectional and longitudinal data, to investigate novel scientific ideas and/or to generate new models, systems, tools, methods, or technologies that have the potential for significant impact on biomedical or biobehavioral research in areas relevant to the Food and Drug Administration (FDA) - Center for Tobacco Products (CTP).

Application Due Dates: October 8, 2019, July 20, 2020, March 8, 2021

[RFA-HL-19-025 \(K01\)](#) – clinical trial required; [RFA-HL-19-026 \(K01\)](#) – clinical trial not allowed

Mentored Career Development Award to Promote Faculty Diversity in Biomedical Research

Applications are invited to enhance the pool of highly trained investigators from diverse backgrounds, including those from groups underrepresented in research areas of interest to the NHLBI. These FOAs are targeted toward individuals whose basic, clinical, and translational research interests are grounded in the advanced methods and experimental approaches needed to solve problems related to cardiovascular, pulmonary, and hematologic diseases and sleep disorders in the general and health disparities populations. **Application Due Dates:** October 10, 2019, February 11, 2020, October 9, 2020, February 11, 2021

[RFA-CA-19-034 \(P20\)](#) – clinical trial optional

Feasibility and Planning Studies for Development of Specialized Programs of Research Excellence (SPOREs) to Investigate Cancer Health Disparities

The P20 grants will support feasibility and planning activities to build comprehensive cancer health disparities research programs. All applications must propose translational research that will contribute to improved prevention, early detection, diagnosis, and/or treatment of cancers found to disproportionately affect specific racial/ethnic minority populations. **Application Due Dates:** October 18, 2019, June 19, 2020, and October 18, 2020

[RFA-HL-19-023 \(T32\)](#) – clinical trial not allowed

T32 Training Program for Institutions that Promote Diversity

The NHLBI's T32 Training Program is intended to support training of predoctoral and health professional students and individuals in postdoctoral training institutions with an institutional mission focused on serving health disparity populations not well represented in scientific research, or institutions that have been identified by federal legislation as having an institutional mission focused on these populations, with the potential to develop meritorious training programs in cardiovascular, pulmonary, and hematologic diseases, and sleep disorders.

Application Due Dates: February 26, 2020; September 4, 2020; February 26, 2021

[RFA-HL-19-024 \(R25\)](#) – clinical trial not allowed

Short-Term Research Education Program to Increase Diversity in Health-Related Research

The over-arching goal of this program is to support educational activities that enhance the diversity of the biomedical, behavioral and clinical research workforce by providing research experiences and related opportunities that enrich the pool of individuals from nationally underrepresented groups who will be available to compete for research opportunities in the mission areas of importance to NHLBI. **Application Due Dates:** February 26, 2020, September 10, 2020, February 26, 2021

[RFA-DA-19-019 \(R43/R44\)](#) – clinical trial optional

[RFA-DA-19-020 \(R41/R42\)](#) – clinical trial optional

America's Startups and Small Businesses Build Technologies to Stop the Opioid Crisis

These FOAs invite applications from US small business concerns to develop technologies to provide science-and research-based solutions to the opioid emergency. **Application Due Dates:** April 9, 2020, September 8, 2020, April 9, 2021, September 8, 2021

Program Announcements with Set-Aside Funds (PAS)

[PAS-19-316 \(R43/R44\)](#); [PAS-19-317 \(R41/R42\)](#) – clinical trial optional

Advancing Research on Alzheimer's Disease (AD) and Alzheimer's-Disease-Related Dementias (ADRD)

These FOAs seek applications to conduct research leading to the development of innovative products and/or services that may advance progress in preventing and treating AD and ADRD and/or caring for and treating AD/ADRD patients.

Application Due Dates: Standard dates apply; **Expiration Date:** September 7, 2022

Program Announcements Reviewed by an Institute (PAR)

[PAR-19-309 \(R21\)](#) – clinical trial optional

Stimulating Innovations in Behavioral Intervention Research for Cancer Prevention and Control

This FOA provides support for the development of innovative interventions that improve cancer-related health behaviors across diverse racial/ethnic populations. The cancer-related health behaviors to be targeted are diet, obesity, physical activity and sedentary behavior, smoking, sleep and circadian dysfunction, alcohol use, and/or adherence to cancer-related medical regimens. **Application Due Dates:** Standard dates apply; **Expiration Date:** September 8, 2022

[PAR-19-310 \(R03\)](#) – clinical trial optional

Behavioral Science Track Award for Rapid Transition (B/Start)

NIDA will support studies that apply affective, cognitive and behavioral science approaches to research questions relevant to substance use disorders (SUD). The B/Start is intended for recently-independent investigators with expertise in behavioral science as well as established investigators who are using behavioral science approaches to SUD for the first time. **Application Due Date:** Standard dates apply; **Expiration Date:** January 8, 2022

SBIR/STTR Commercialization Readiness Pilot (CRP) Programs (SB1/R44)

The FOAs listed below aim to facilitate the transition of previously or currently funded SBIR and STTR Phase II and Phase IIB projects to the commercialization stage by providing additional support for technical assistance and later stage research and development (R&D) not typically supported through Phase II or Phase IIB grants or contracts:

Application Due Dates: Standard dates apply; **Expiration Date:** April 6, 2022

[PAR-19-333](#) - clinical trial not allowed; [PAR-19-335](#) – clinical trial required

This may include independent replication of key studies, Investigational New Drug (IND)-enabling studies, clinical studies, manufacturing costs, regulatory assistance, or a combination of services.

[PAR-19-334](#) – clinical trial not allowed

This may include preparation of documents for a Food and Drug Administration (FDA) submission, development of an intellectual property strategy, and/or planning for a clinical trial.

Fellowships

[RFA-AG-20-009 \(F99/K00\)](#)

Transition to Aging Research for Predoctoral Students

NIA invites outstanding graduate students from a wide range of broad research areas including, but not limited to, statistics, neuroscience, physics, immunology, microbiology, informatics, data sciences, and engineering who are interested in receiving aging-related postdoctoral training to apply for this award. This two-phase award will allow awardees to complete doctoral dissertation projects and provide a variety of training supports to facilitate smooth transition of doctoral graduates into competitive, aging-focused postdoctoral positions.

Application Deadline: October 22, 2019

[RFA-OD-18-007 \(K99/R00\)](#) – clinical trial not allowed; [RFA-OD-18-008 \(K99/R00\)](#) – clinical trial required

Pathway to Independence Award in Tobacco Regulatory Research

The purpose of this award is to increase and maintain a strong cohort of new and talented independent investigators conducting research that will inform the development and evaluation of regulations on tobacco product manufacturing, distribution, and marketing. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. **Application Due Dates:** November 8, 2019

FOUNDATION FUNDING OPPORTUNITIES

Robert Wood Johnson Foundation

[System for Action](#), a signature research program of the Foundation, is issuing a call for proposals to support rigorous testing of new ways to connect the nation's fragmented medical, social, and public health systems. All proposals must test specific actions that an organization, network, or community undertakes to reduce fragmentation and improve coordination. Researchers with underrepresented backgrounds, from disciplines outside of the health and medical science sectors and academic settings, and/or who have not previously received RWJF funding are encouraged to apply. Up to four awards of \$500K are available. Webinars will be held September 5th at 1 pm or October 1st at 11 am. Registration is required and can be completed [here](#). **Application Due Date:** November 6, 2019

